Early Treatment Consideration in Patients with Hepatitis B ‘e’ Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift?

Chronic hepatitis B (CHB) is associated with significant morbidity and mortality, due to the adverse sequelae of cirrhosis and hepatocellular carcinoma (HCC). To date, antiviral therapy has been reserved for patients with ostensibly active liver disease, fibrosis or cirrhosis, and/or increased risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Koffas, Apostolos, Mak, Lung-Yi, Gill, Upkar S., Kennedy, Patrick T. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143099/
https://www.ncbi.nlm.nih.gov/pubmed/35632642
http://dx.doi.org/10.3390/v14050900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143099/
https://www.ncbi.nlm.nih.gov/pubmed/35632642
http://dx.doi.org/10.3390/v14050900

Ejemplares similares